Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Capital Expenditures (2016 - 2025)

Editas Medicine (EDIT) has disclosed Capital Expenditures for 11 consecutive years, with $547000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures fell 93.36% to $547000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$7.7 million through Sep 2025, down 234.18% year-over-year, with the annual reading at $65000.0 for FY2024, 92.31% down from the prior year.
  • Capital Expenditures for Q3 2025 was $547000.0 at Editas Medicine, up from -$114000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $8.2 million in Q3 2024, with the low at -$8.2 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $572315.8, with a median of $467000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 3344.35% in 2024, while the deepest fall reached 236.31% in 2024.
  • Over 5 years, Capital Expenditures stood at $7.4 million in 2021, then plummeted by 127.83% to -$2.1 million in 2022, then fell by 24.98% to -$2.6 million in 2023, then crashed by 220.26% to -$8.2 million in 2024, then soared by 106.65% to $547000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $547000.0, -$114000.0, and $114000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.